Leerink downgrades Pliant Therapeutics after trial discontinuation
Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...
Leerink Partnrs Estimates Kura Oncology FY2026 Earnings
Equities research analysts at Leerink Partnrs issued their FY2026 EPS estimates for Kura Oncology in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang ...
Hosted on MSN13d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform Recommendation
Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
FiercePharma13d
Leerink group goes beyond conventional metrics to evaluate cost-effectiveness of key therapies
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...
Q1 Earnings Estimate for argenx Issued By Leerink Partnrs
Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for argenx in a research report issued to clients ...
Business Insider3y
SVB Leerink has staffed up with at least 18 hires to chase hot tech deals — and adding ECM and fintech bankers is next
Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...